BMC Nephrology (Mar 2022)

Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?

  • Nicole Nourié,
  • Hussein Nassereddine,
  • Sarah Mouawad,
  • Louaa Chebbou,
  • Rita Ghaleb,
  • Fatmeh Abbas,
  • Hiba Azar

DOI
https://doi.org/10.1186/s12882-022-02713-x
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Antibody-mediated rejection (AMR) was described in kidney transplant patients after viral infections, such as the cytomegalovirus. Very few cases were recently reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, probably in the context of lowering of immunosuppressive therapy. To date, no direct immunological link was proved to explain a connection between the coronavirus disease 19 (COVID-19) infection and antibody-mediated rejection (AMR) if it exists. Case presentation Here we try to find this association by presenting the case of a low immunological risk patient who presented, six years post-transplant, with c4d negative antibody mediated rejection due to an anti-HLA-C17 de novo donor specific antibody (DSA) after contracting the coronavirus disease 19. The HLA-Cw17 activated the antibody-dependent cell-mediated cytotoxicity via the KIR2DS1 positive NK cells. Discussion and conclusions This case report may prove a direct role for COVID-19 infection in AMRs in the kidney transplant recipients, leading us to closely monitor kidney transplant recipients, especially if they have “at-risk” donor antigens.

Keywords